Published in Am J Pathol on October 01, 2004
Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol (2005) 3.19
Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am J Pathol (2009) 3.09
Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol (2005) 1.19
Laser capture microdissection in the genomic and proteomic era: targeting the genetic basis of cancer. Int J Clin Exp Pathol (2008) 1.00
Recurrent prostatic stromal sarcoma with massive high-grade prostatic intraepithelial neoplasia. J Clin Pathol (2007) 0.90
Laser capture microdissection: Big data from small samples. Histol Histopathol (2015) 0.85
A subset of malignant phyllodes tumors harbors alterations in the Rb/p16 pathway. Hum Pathol (2013) 0.83
The steroid receptor coactivator-3 is required for developing neuroendocrine tumor in the mouse prostate. Int J Biol Sci (2014) 0.82
Beyond laser microdissection technology: follow the yellow brick road for cancer research. Am J Cancer Res (2014) 0.81
The identification of trans-associations between prostate cancer GWAS SNPs and RNA expression differences in tumor-adjacent stroma. Oncotarget (2015) 0.76
Metastatic prostatic stromal sarcoma: A challenging diagnosis on fine-needle aspiration with broad differential diagnosis. Cytojournal (2017) 0.75
The p53 tumour suppressor gene. Nature (1991) 14.49
Laser capture microdissection: molecular analysis of tissue. Science (1997) 3.93
Sarcomas and related proliferative lesions of specialized prostatic stroma: a clinicopathologic study of 22 cases. Am J Surg Pathol (1998) 3.10
Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A (1991) 2.27
Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol (1995) 1.85
Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res (1995) 1.85
Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst (1998) 1.81
Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res (1996) 1.78
Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential. J Natl Cancer Inst (2001) 1.65
p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res (1993) 1.59
Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer. Cancer Res (1995) 1.57
Clonal analysis of fibroadenoma and phyllodes tumor of the breast. Cancer Res (1993) 1.51
Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl (1993) 1.28
Allelic imbalance in the clonal evolution of prostate carcinoma. Cancer (1999) 1.22
Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. Cancer (1998) 1.18
Malignant phyllodes tumor of the prostate: retrospective review of specimens obtained by sequential transurethral resection. Pathol Int (2002) 1.14
Molecular analysis of phyllodes tumors reveals distinct changes in the epithelial and stromal components. Am J Pathol (2000) 1.09
Malignant phyllodes tumor of prostate. Urology (1990) 1.04
An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res (1996) 1.03
Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytomas. Cancer Res (1992) 1.00
Nephroblastoma arising in a germ cell tumor of testicular origin. Am J Surg Pathol (2004) 0.97
Molecular genetic evidence for different clonal origin of components of human renal angiomyolipomas. Am J Surg Pathol (2001) 0.97
Atypical adenomatous hyperplasia of the prostate: a premalignant lesion? Cancer Res (1998) 0.92
p53 mutations and prognosis in bladder tumors. J Urol (1995) 0.91
PCR techniques for clonality assays. Diagn Mol Pathol (2001) 0.90
Identical allelic losses in mature teratoma and other histologic components of malignant mixed germ cell tumors of the testis. Am J Pathol (2003) 0.90
Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor. Cancer (2002) 0.89
p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cancer (1999) 0.89
Molecular evidence supporting the neoplastic nature of some epidermoid cysts of the testis. Arch Pathol Lab Med (2003) 0.86
Stroma adjacent to metastatic mature teratoma after chemotherapy for testicular germ cell tumors is derived from the same progenitor cells as the teratoma. Cancer Res (2003) 0.86
Sex hormone metabolism in prostate cancer cells during transition to an androgen-independent state. J Clin Endocrinol Metab (2003) 0.85
Prostatic cystic epithelial-stromal tumors: a report of 2 new cases. J Urol (1993) 0.85
Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression. Clin Cancer Res (1999) 0.84
Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder. Cancer (2004) 0.84
Phenotypic effects of overexpression of the MMAC1 gene in prostate epithelial cells. Br J Cancer (2000) 0.82
p53 alteration in regional lymph node metastases from prostate carcinoma: a marker for progression? Cancer (1999) 0.82
Phyllodes type of atypical prostatic hyperplasia: a report of 3 new cases. J Urol (1987) 0.82
Conserved genetic findings in metastatic bladder cancer: a possible utility of allelic loss of chromosomes 9p21 and 17p13 in diagnosis. Arch Pathol Lab Med (2001) 0.81
Phyllodes type of atypical prostatic hyperplasia. J Urol (1976) 0.77
Malignant cystosarcoma phyllodes of prostate. Acta Pathol Jpn (1984) 0.77
Cystosarcoma phyllodes of the prostate. Scand J Urol Nephrol (1996) 0.76
High grade phyllodes tumour of the prostate. Arch Ital Urol Androl (1999) 0.76
Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78
On the practice of dichotomization of quantitative variables. Psychol Methods (2002) 9.18
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry (2006) 3.72
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol (2013) 3.68
Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology (2005) 3.40
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. Cell (2008) 2.84
The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol (2007) 2.70
Tensegrity: construction of rigid DNA triangles with flexible four-arm DNA junctions. J Am Chem Soc (2004) 2.40
Cystic nephroma and mixed epithelial and stromal tumour of the kidney: opposite ends of the spectrum of the same entity? Eur Urol (2007) 2.33
Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol (2009) 2.30
Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer (2004) 2.22
Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol (2007) 2.20
Immunoglobulin G4-related disease in genitourinary organs: an emerging fibroinflammatory entity often misdiagnosed preoperatively as cancer. Eur Urol (2012) 2.18
Radial distance of extraprostatic extension measured by ocular micrometer is an independent predictor of prostate-specific antigen recurrence: A new proposal for the substaging of pT3a prostate cancer. Am J Surg Pathol (2007) 2.17
Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies. Am J Surg Pathol (2010) 2.16
Immunohistochemical markers in the evaluation of tumors of the urinary bladder: a review. Anal Quant Cytol Histol (2005) 2.14
Feasibility of omitting cortical renorrhaphy during robot-assisted partial nephrectomy: a matched analysis. J Endourol (2015) 2.05
Words of wisdom: re: multilocular cystic renal cell carcinoma with focus on clinical and pathobiological aspects. Eur Urol (2013) 2.00
OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma. Am J Surg Pathol (2004) 1.99
Benign metastasizing leiomyoma: clonality, telomere length and clinicopathologic analysis. Mod Pathol (2006) 1.87
Multimodal imaging guided photothermal therapy using functionalized graphene nanosheets anchored with magnetic nanoparticles. Adv Mater (2012) 1.86
Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer (2004) 1.85
FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res (2011) 1.80
Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol (2006) 1.80
Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. Eur Urol (2010) 1.79
Phyllodes tumor of the prostate: long-term followup study of 23 cases. J Urol (2004) 1.77
Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol (2010) 1.73
Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol (2008) 1.72
Toward a method of selecting among computational models of cognition. Psychol Rev (2002) 1.72
Neuroendocrine tumours of the urinary system and male genital organs: clinical significance. BJU Int (2009) 1.71
Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. J Urol (2007) 1.69
Histological changes of minimally invasive procedures for the treatment of benign prostatic hyperplasia and prostate cancer: clinical implications. J Urol (2003) 1.68
Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. Am J Surg Pathol (2008) 1.64
Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas. Clin Cancer Res (2005) 1.63
Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol (2010) 1.61
Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors. Hum Pathol (2008) 1.60
Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst (2009) 1.59
ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol (2011) 1.59
Multivariate statistical differentiation of renal cell carcinomas based on lipidomic analysis by ambient ionization imaging mass spectrometry. Anal Bioanal Chem (2010) 1.58
The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. Hum Pathol (2007) 1.53
Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol (2004) 1.53
Phase I/II trial of high intensity focused ultrasound for the treatment of previously untreated localized prostate cancer. J Urol (2007) 1.53
Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res (2004) 1.53
Soft tissue tumors of the urinary bladder, Part I: myofibroblastic proliferations, benign neoplasms, and tumors of uncertain malignant potential. Hum Pathol (2007) 1.52
Original Gleason system versus 2005 ISUP modified Gleason system: the importance of indicating which system is used in the patient's pathology and clinical reports. Eur Urol (2010) 1.51
Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol (2012) 1.50
Cholesterol sulfate imaging in human prostate cancer tissue by desorption electrospray ionization mass spectrometry. Anal Chem (2010) 1.48
Incidence, histology and management of intraluminal thrombus at post-chemotherapy retroperitoneal lymph node dissection. J Urol (2013) 1.48
Plasmacytoid urothelial carcinoma of the bladder. Hum Pathol (2009) 1.46
Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer (2004) 1.45
Role of molecular markers in diagnosis and prognosis of renal cell carcinoma. Anal Quant Cytol Histol (2007) 1.45
Biopsy misidentification identified by DNA profiling in a large multicenter trial. J Clin Oncol (2011) 1.44
Does antidepressant use attenuate the risk of a major depressive episode in pregnancy? Epidemiology (2011) 1.44
Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol (2002) 1.43
2009 update on the classification of renal epithelial tumors in adults. Int J Urol (2009) 1.43
Endoloop-assisted laparoscopic partial nephrectomy. J Endourol (2002) 1.42
Evidence supporting the existence of benign teratomas of the postpubertal testis: a clinical, histopathologic, and molecular genetic analysis of 25 cases. Am J Surg Pathol (2013) 1.42
High-grade prostatic intraepithelial neoplasia. Mod Pathol (2004) 1.40
Immunohistochemical expression of endothelin-1 and endothelin-A and endothelin-B receptors in high-grade prostatic intraepithelial neoplasia and prostate cancer. Eur Urol (2007) 1.39
Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy. Virchows Arch (2007) 1.39
Rare and unusual histological variants of prostatic carcinoma: clinical significance. BJU Int (2008) 1.36
High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol (2003) 1.35
Nondestructive, histologically compatible tissue imaging by desorption electrospray ionization mass spectrometry. Chembiochem (2011) 1.34
OCT4: A sensitive and specific biomarker for intratubular germ cell neoplasia of the testis. Clin Cancer Res (2004) 1.34
Prostatic stromal hyperplasia with atypia: follow-up study of 18 cases. Arch Pathol Lab Med (2008) 1.33
Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol (2010) 1.33
Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res (2008) 1.33
Drug delivery with upconversion nanoparticles for multi-functional targeted cancer cell imaging and therapy. Biomaterials (2010) 1.33
Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Pathol (2002) 1.31
Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. Hum Pathol (2006) 1.31
Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol (2006) 1.29
Multivariate statistical identification of human bladder carcinomas using ambient ionization imaging mass spectrometry. Chemistry (2011) 1.28
TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum. Am J Surg Pathol (2013) 1.28